IOncology

Editor’s Note: Non–clear cell renal cell carcinoma (nccRCC) remains one of the most challenging areas in kidney cancer owing to its marked heterogeneity, low incidence, and complexity in diagnosis and…

From “following evidence” to “creating evidence”, clinical research in breast cancer in China is entering a deep phase of high-quality development. Within the grand framework of precision medicine, industry-sponsored trials (ISTs) may serve as the gateway for innovative drugs to enter clinical practice, but investigator-initiated trials (IITs) are the master key to solving the “last mile” problems of real-world clinical application.

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a reanalysis of the landmark NSABP B-20 trial (Abstract No. RF3-03) was presented, exploring the prognostic value and chemotherapy benefit–predictive potential of a multimodal artificial intelligence (MMAI) model based on digital pathology and clinical data in hormone receptor–positive (HR+), node-negative early breast cancer.

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study based on data from the NSABP B-42 and TAILORx trials (Abstract No. RF3-07) reported the development and validation of a multimodal, multitask deep learning model (Clarity BCR). By integrating routine digital pathology images with key clinical variables, this model accurately predicts the risk of late distant recurrence (late DR) in patients with hormone receptor–positive (HR+) early breast cancer and effectively identifies those who may benefit from extended endocrine therapy (EET).

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study titled “Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. The study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early triple-negative breast cancer (TNBC), revealing the predictive value of tumor-infiltrating lymphocytes (TILs) and molecular TNBC subtypes for treatment efficacy.

In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.

De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.

| 15th Shanghai Urologic Oncology Academic ConferencePlay Editor’s Note: With the continuous evolution of treatment concepts and the advancement of therapeutic strategies, the management landscape of muscle-invasive bladder cancer…

| The 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was held in Pudong, Shanghai, bringing together leading experts in urologic oncology from…

Editor’s Note: De-escalation and precision tailoring of neoadjuvant therapy have become major trends in the management of HER2-positive early breast cancer, yet accurately predicting pathological response at an early stage…